Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
:NNVC
Top Page
NanoViricides
(NYSE MKT:NNVC)
38Underperform
NanoViricides (NNVC) vs. S&P 500 (SPY)
Market Cap
$17.83M
Dividend YieldN/A
Average Volume (3M)176.28K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth10.23%
CountryUS
Employees7
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,641,000
10 Day Avg. Volume85,186
30 Day Avg. Volume176,285
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoViricides Business Overview & Revenue Model
Company DescriptionNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
How the Company Makes MoneyNanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.
NanoViricides Financial Statement Overview
Summary
NanoViricides is facing significant financial challenges characterized by lack of revenue, consistent operational losses, and cash burn. While the capital structure shows no debt, the reliance on equity and financing for operations underscores the urgency for revenue generation to ensure long-term viability.Income Statement
NanoViricides has not generated any revenue in the TTM (Trailing-Twelve-Months) or previous years, leading to consistent negative gross and net profit margins. The company operates at a loss with EBIT and EBITDA margins also being negative, indicating ongoing financial challenges.20
Very Negative
Balance Sheet
The company maintains a favorable debt position with zero total debt in the latest TTM, resulting in a strong equity ratio. However, the declining stockholders' equity and total assets over time suggest potential concerns regarding asset management and equity preservation.50
Neutral
Cash Flow
NanoViricides has negative operating and free cash flows, indicating cash burn without revenue generation. The company relies on financing activities to support operations, which may not be sustainable long-term without revenue growth.35
Negative
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -380.56K | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K | EBIT |
| -9.53M | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M | EBITDA |
| -8.63M | -7.76M | -7.84M | -7.38M | -8.03M | -7.30M | Net Income Common Stockholders |
| -9.36M | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.96M | 4.80M | 8.15M | 14.07M | 20.52M | 13.71M | Total Assets |
| 11.57M | 12.82M | 16.90M | 23.49M | 30.26M | 23.91M | Total Debt |
| 0.00 | 0.00 | 0.00 | 94.79K | 95.31K | 1.14M | Net Debt |
| -3.96M | -4.80M | -8.15M | -13.97M | -20.42M | -12.56M | Total Liabilities |
| 1.18M | 1.36M | 2.03M | 412.84K | 351.15K | 2.16M | Stockholders Equity |
| 10.39M | 11.46M | 14.87M | 23.08M | 29.91M | 21.76M |
| Cash Flow | Free Cash Flow | ||||
| -8.40M | -6.47M | -5.82M | -6.22M | -8.45M | -6.67M | Operating Cash Flow |
| -8.21M | -6.32M | -5.67M | -5.89M | -8.21M | -6.67M | Investing Cash Flow |
| -189.56K | -156.56K | -151.71K | -324.35K | -238.76K | -8.64K | Financing Cash Flow |
| 7.11M | 3.12M | -94.79K | -234.72K | 15.26M | 17.83M |
NanoViricides Technical Analysis
Negative
1.14
Price Trends
1.25
Negative
1.32
Negative
1.53
Negative
Market Momentum
-0.02
Positive
41.54
Neutral
13.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.25, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.54 is Neutral, neither overbought nor oversold. The STOCH value of 13.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 50 risk factors in its most recent earnings report. NanoViricides reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NanoViricides Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $84.91M | ― | -114.71% | ― | 288.94% | 39.45% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $9.93B | ― | -28.77% | ― | -52.75% | 25.00% | |
39 Underperform | $965.07M | ― | 30.06% | ― | -30.65% | 77.62% | |
38 Underperform | $17.83M | ― | -82.01% | ― | ― | 10.23% | |
34 Underperform | $58.30M | ― | -115.42% | ― | -73.83% | 34.81% |
* Healthcare Sector Average
Performance Comparison
NNVC
NanoViricides
1.14
-0.23
-16.79%
INO
Inovio Pharmaceuticals
1.59
-10.21
-86.53%
NVAX
Novavax
5.60
1.18
26.70%
VXRT
Vaxart
0.38
-0.70
-64.81%
CYDY
CytoDyn
0.23
0.06
35.29%
MRNA
Moderna
25.73
-77.15
-74.99%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.